Literature DB >> 16462527

Basic calcium phosphate crystals: pathways to joint degeneration.

Eamonn S Molloy1, Geraldine M McCarthy.   

Abstract

PURPOSE OF REVIEW: Basic calcium phosphate crystals have long been associated with rheumatic syndromes. Although an understanding of the molecular mechanisms involved in generating these pathological effects has been significantly advanced in recent years, it is still incomplete. RECENT
FINDINGS: Basic calcium phosphate crystals have been shown to increase prostaglandin E(2) production in human fibroblasts, mediated by the induction of both cyclooxygenases 1 and 2. Basic calcium phosphate crystals have also been found to upregulate IL-1beta in fibroblasts and chondrocytes. The upregulation of inducible nitric oxide synthase and stimulation of nitric oxide production in chondrocytes by octacalcium phosphate crystals has been demonstrated. The involvement of protein kinase C isoforms in basic calcium phosphate crystal-mediated matrix metalloproteinase 1 and 3 expression in human fibroblasts has been clarified. Two pathways are involved: protein kinase Calpha mediates the calcium-dependent pathway, whereas protein kinase Cmu activates the extracellular-regulated kinase pathway in a calcium-independent cascade. In addition, basic calcium phosphate crystals activate the transcription factor Egr-1, an effect that may contribute to the mitogenic effect of these crystals on fibroblasts.
SUMMARY: Recent findings have emphasized the potential for basic calcium phosphate crystals to stimulate the production of a variety of inflammatory mediators such as prostaglandin E(2), nitric oxide, IL-1beta and matrix metalloproteinases, and have helped to elucidate the mechanisms of these effects. Such advances are essential for the ongoing search for effective therapies for basic calcium phosphate crystal-associated diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462527     DOI: 10.1097/01.bor.0000209433.43978.a8

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

1.  Does primary or secondary chondrocalcinosis influence long-term survivorship of unicompartmental arthroplasty?

Authors:  Philippe Hernigou; Walter Pascale; Valerio Pascale; Yasuhiro Homma; Alexandre Poignard
Journal:  Clin Orthop Relat Res       Date:  2011-12-13       Impact factor: 4.176

2.  Calcium orthophosphates (CaPO4): occurrence and properties.

Authors:  Sergey V Dorozhkin
Journal:  Prog Biomater       Date:  2015-11-19

3.  Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis.

Authors:  Dov Hershkovitz; Yonit Gross; Sagi Nahum; Shiran Yehezkel; Ofer Sarig; Jouni Uitto; Eli Sprecher
Journal:  J Invest Dermatol       Date:  2010-12-16       Impact factor: 8.551

4.  Salivary antioxidants and metalloproteinases in juvenile idiopathic arthritis.

Authors:  Riva Brik; Irit Rosen; Dana Savulescu; Iris Borovoi; Moshe Gavish; Rafael Nagler
Journal:  Mol Med       Date:  2009-12-28       Impact factor: 6.354

Review 5.  Calcium orthophosphates: occurrence, properties, biomineralization, pathological calcification and biomimetic applications.

Authors:  Sergey V Dorozhkin
Journal:  Biomatter       Date:  2011 Oct-Dec

Review 6.  Comorbidities in patients with crystal diseases and hyperuricemia.

Authors:  Sebastian E Sattui; Jasvinder A Singh; Angelo L Gaffo
Journal:  Rheum Dis Clin North Am       Date:  2014-02-19       Impact factor: 2.670

7.  Chondrocyte-derived exosomes promote cartilage calcification in temporomandibular joint osteoarthritis.

Authors:  Qian Liu; Ruoxin Wang; Shujie Hou; Feng He; Yuanjun Ma; Tao Ye; Shibin Yu; Hongwei Chen; Helin Wang; Mian Zhang
Journal:  Arthritis Res Ther       Date:  2022-02-14       Impact factor: 5.156

Review 8.  Detection of calcium phosphate crystals in the joint fluid of patients with osteoarthritis - analytical approaches and challenges.

Authors:  Alexander Yavorskyy; Aaron Hernandez-Santana; Geraldine McCarthy; Gillian McMahon
Journal:  Analyst       Date:  2008-02-01       Impact factor: 4.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.